

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 23, 2025

Purified anti-human CD137 (4-1BB)

RRID:AB_314781

Type: Antibody

Proper Citation

(BioLegend Cat# 309802, RRID:AB_314781)

Antibody Information

URL: http://antibodyregistry.org/AB_314781

Proper Citation: (BioLegend Cat# 309802, RRID:AB_314781)

Target Antigen: CD137

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, IP, ELISA

Antibody Name: Purified anti-human CD137 (4-1BB)

Description: This monoclonal targets CD137

Target Organism: human

Clone ID: Clone 4B4-1

Antibody ID: AB_314781

Vendor: BioLegend

Catalog Number: 309802

Record Creation Time: 20231110T044956+0000

Record Last Update: 20241115T082408+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD137 (4-1BB).

No alerts have been found for Purified anti-human CD137 (4-1BB).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. *Cancer cell*, 41(5), 837.

van der Sluis TC, et al. (2023) OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. *Cell reports. Medicine*, 4(3), 100939.

Zhu Y, et al. (2023) Opioid-induced fragile-like regulatory T cells contribute to withdrawal. *Cell*, 186(3), 591.

Lukhele S, et al. (2022) The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity. *Immunity*, 55(12), 2369.

Loo Yau H, et al. (2021) DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells. *Molecular cell*, 81(7), 1469.

Friebel E, et al. (2020) Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes. *Cell*, 181(7), 1626.

Rodriguez L, et al. (2020) Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. *Cell reports. Medicine*, 1(5), 100078.

Lavin Y, et al. (2017) Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. *Cell*, 169(4), 750.